Sacituzumab govitecan (Immunomedics) is an antibody-drug conjugate consisting of an anti-troponin (Trop)-2 antibody conjugated to SN-38. Trop-1 and Trop-2 are type I membrane proteins expressed in human epithelial cells at various stages of differentiation. Trop-1 and Trop-2 are located at contact sites between adjacent cells, where they bind to each other and take part in the formation of specialized cell-cell adhesion structures. Overexpression of Trop-2 has been demonstrated to be necessary and sufficient to stimulate tumor growth. Expression of Trop-1 and Trop-2 is associated with poor prognosis of several human cancers, including oral, pancreatic, gastric, ovarian, colorectal, breast, and lung tumors.
SN-38 is the active metabolite of irinotecan, an analog of camptothecin. SN-38 prevents DNA from unwinding by inhibition of topoisomerase I. SN-38 is moderately toxic, allowing it to be conjugated at a drug-to-antibody ratio (DAR) of 7.6:1, which is approximately twice the DAR of other antibody-drug conjugates. Following the binding to Trop-2, the antibody-drug conjugate is internalized into the cell where it releases SN-38, thus delivering a concentrated dose of SN-38 to the tumor.
4 Drug Overview
5 Product Profiles
5 sacituzumab govitecan : Breast cancer: triple-negative
LIST OF FIGURES
10 Figure 1: Datamonitor Healthcare’s drug assessment summary of sacituzumab govitecan for TNBC
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of sacituzumab govitecan for TNBC
LIST OF TABLES
5 Table 1: Recent high-impact events for sacituzumab govitecan in TNBC
6 Table 2: Sacituzumab govitecan drug profile
8 Table 3: Late-phase trials of sacituzumab govitecan for TNBC
9 Table 4: Sacituzumab govitecan for TNBC – SWOT analysis
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.